Nursing Guide for Second-Line Tuberculosis Medications

Tuberculosis and Hansen’s Disease Unit
Drug Resistant TB Monitoring Program
December 2021
# Table of Contents

<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Introduction</td>
<td>3</td>
</tr>
<tr>
<td>Overview of Second-Line TB Medications</td>
<td>4</td>
</tr>
<tr>
<td>Aminoglycosides/Injectable Agents</td>
<td>4</td>
</tr>
<tr>
<td>Side Effects and Symptoms of Medication Toxicity</td>
<td>4</td>
</tr>
<tr>
<td>Recommended Assessments and Monitoring</td>
<td>4</td>
</tr>
<tr>
<td>Bedaquiline (BDQ)</td>
<td>5</td>
</tr>
<tr>
<td>Side Effects and Symptoms of Medication Toxicity</td>
<td>5</td>
</tr>
<tr>
<td>Recommended Assessments and Monitoring</td>
<td>5</td>
</tr>
<tr>
<td>Clofazimine (CFZ)</td>
<td>6</td>
</tr>
<tr>
<td>Side Effects and Symptoms of Medication Toxicity</td>
<td>6</td>
</tr>
<tr>
<td>Recommended Assessments and Monitoring</td>
<td>6</td>
</tr>
<tr>
<td>Cycloserine (CS)</td>
<td>7</td>
</tr>
<tr>
<td>Side Effects and Symptoms of Medication Toxicity</td>
<td>7</td>
</tr>
<tr>
<td>Recommended Assessments and Monitoring</td>
<td>7</td>
</tr>
<tr>
<td>Ethionamide (ETA)</td>
<td>8</td>
</tr>
<tr>
<td>Side Effects and Symptoms of Medication Toxicity</td>
<td>8</td>
</tr>
<tr>
<td>Recommended Assessments and Monitoring</td>
<td>8</td>
</tr>
<tr>
<td>Fluoroquinolones (FQN) — Levofloxacin and Moxifloxacin</td>
<td>9</td>
</tr>
<tr>
<td>Side Effects and Symptoms of Medication Toxicity</td>
<td>10</td>
</tr>
<tr>
<td>Recommended Assessments and Monitoring</td>
<td>10</td>
</tr>
<tr>
<td>High Dose Isoniazid (INH)</td>
<td>11</td>
</tr>
<tr>
<td>Side Effects and Symptoms of Medication Toxicity</td>
<td>11</td>
</tr>
<tr>
<td>Recommended Assessments and Monitoring</td>
<td>11</td>
</tr>
<tr>
<td>Linezolid (LZD)</td>
<td>12</td>
</tr>
<tr>
<td>Side Effects and Symptoms of Medication Toxicity</td>
<td>12</td>
</tr>
<tr>
<td>Recommended Assessments and Monitoring</td>
<td>13</td>
</tr>
<tr>
<td>Para-Aminosalicylic Acid (PAS)</td>
<td>14</td>
</tr>
<tr>
<td>Side Effects and Symptoms of Medication Toxicity</td>
<td>14</td>
</tr>
<tr>
<td>Recommended Assessments and Monitoring</td>
<td>14</td>
</tr>
<tr>
<td>Pretomanid (Pa)</td>
<td>15</td>
</tr>
<tr>
<td>Side Effects and Symptoms of Medication Toxicity</td>
<td>15</td>
</tr>
<tr>
<td>Recommended Assessments and Monitoring</td>
<td>15</td>
</tr>
<tr>
<td>Fact Sheets and Medication Resources</td>
<td>16</td>
</tr>
<tr>
<td>Nursing Cheat Sheets</td>
<td>19</td>
</tr>
<tr>
<td>References</td>
<td>20</td>
</tr>
</tbody>
</table>
Introduction

The purpose of this guide is to provide TB nurse case managers with:

- An overview of second-line TB medications;
- Fact sheets and resources to support patient education;
- Nursing cheat sheets on medication-related recommendations; and
- Recommended references.

Clinicians prescribe second-line medications to treat certain types of tuberculosis (TB), including drug-resistant TB (DR-TB). Clinicians may recommend second-line TB medications for patients with drug-susceptible TB disease who are intolerant to first-line medications. Although these medications have known side effects, they are necessary and at times the only option to treat TB.

Nurses should understand each drug and the associated monitoring, which can minimize potential adverse reactions. In addition, an element of patient-centered care is educating patients and families on their treatment plans to promote medication adherence. The guide is designed to supplement the nurses’ knowledge of second-line medications and should be used along with orders by the treating physician.
Overview of Second-Line TB Medications

This section outlines potential side effects and toxicities associated with each drug and summarizes recommended assessments.

Aminoglycosides/Injectable Agents

- Amikacin (AK), 1g/4mL vial:

Side Effects and Symptoms of Medication Toxicity

- **General** — Rash or swelling of the face, shortness of breath (SOB), decreased urination, renal toxicity, electrolyte imbalance, muscle twitching or weakness, pain at injection site
- **Ototoxicity** — Hearing loss, tinnitus
- **Vestibular Disturbance** — Dizziness, loss of balance

Recommended Assessments and Monitoring

- **Baseline, Monthly:**
  - Medication Assessments
    - Toxicity Assessment
    - Audiometry Testing
    - Vestibular Testing
  - Laboratory
    - Complete Blood Count (CBC), Comprehensive Metabolic Panel (CMP), and magnesium
- **Other:**
  - Adjust dose, interval for renal insufficiency, or both.
  - Rule out pregnancy prior to administering drug.
  - Aminoglycosides can cause permanent hearing loss. Early intervention is crucial.
Bedaquiline (BDQ)

- 100mg tablet:

Side Effects and Symptoms of Medication Toxicity

- **General** — Hepatotoxicity, headaches, arthralgias, rash
- **Cardiac** — Corrected QT interval (QTc) prolongation; chest pain, SOB, fainting or near fainting, sudden fatigue, change in heart rhythm, tachycardia, syncope

Recommended Assessments and Monitoring

- **Baseline:**
  - Medication Assessments
    - Toxicity Assessment
    - Cardiac monitoring or Electrocardiogram (ECG)
  - Laboratory
    - CBC, CMP, Thyroid-Stimulating Hormone (TSH) and Magnesium
- **At two weeks:**
  - ECG
- **Monthly:**
  - Toxicity Assessment
  - Cardiac Monitoring or ECG
  - CBC, CMP and Magnesium
- **Every three months:**
  - TSH
- **Other:**
  - Monitor for signs and symptoms of prolonged QTc interval.
  - Swallow tablet whole and take with food.
  - Avoid alcohol.
Clofazimine (CFZ)

- 100mg tablet:

Side Effects and Symptoms of Medication Toxicity

- **General** — Bloody or black stools or diarrhea, jaundice, retinopathy, photosensitivity, acne, rare instance-depression or thoughts of hurting self
- **Skin Discoloration** — Clofazimine is a dye and may cause skin discoloration and ichthyosis, xerosis. Hyperpigmentation resolves 1–2 years after discontinuation.
- **GI Intolerance** — Severe abdominal symptoms, bleeding and bowel obstruction
- **Cardiac** — Can cause prolongation of QTc

Recommended Assessments and Monitoring

- **Baseline, monthly:**
  - Medication Assessments
    - Toxicity Assessment
    - Mental Health Assessment
  - Laboratory
    - CBC, CMP
- **Every three months:**
  - Follow-up Assessment (with prescribing physician)
  - Clofazimine Monitoring Form
- **Other:**
  - Prescriber must enroll in the Institutional Review Board (IRB) program to prescribe CFZ.
  - Recommend sunscreen.
  - Rule out pregnancy prior to administering drug.
Cycloserine (CS)

- 250mg capsule:

Side Effects and Symptoms of Medication Toxicity

- **General** — Rash, hives, headaches, seizures, insomnia
- **Depression and Suicidal Ideation** — Mental status or mood changes, aggression, depression, disorientation, hallucinations, inability to concentrate, lethargy, nightmares, slurred speech, suicidal thoughts, psychosis

Recommended Assessments and Monitoring

- **Baseline, monthly:**
  - Medication Assessments
    - Toxicity Assessment
    - Mental Health Assessment
  - Laboratory
    - CBC, CMP

- **Other:**
  - Adjust with renal failure.
  - **Use Vitamin B6** when giving Cycloserine.
  - Avoid alcohol.
Ethionamide (ETA)

- 250mg tablet:

Side Effects and Symptoms of Medication Toxicity

- **General** — Change in vision, headaches, photosensitivity, neuropathy, gastrointestinal (GI) upset, hepatotoxicity, dizziness, hypoglycemia, peripheral neuropathy, hypersensitivity, hypotension, mental disturbance
- **Hypothyroidism** — Unusual bruising or bleeding, increased tiredness, hair loss, skin changes, trouble concentrating, irritable, depression, irregular menses, metallic taste, salivation, gynecomastia, impotence

Recommended Assessments and Monitoring

- **Baseline, Monthly:**
  - Toxicity Assessment
    - Assess for changes in vision
  - Laboratory
    - CBC, CMP and TSH
- **Every three months:**
  - TSH
Fluoroquinolones (FQN) — Levofloxacin and Moxifloxacin

**Levofloxacin (LFX)**
- 250mg tablets (varies depending on manufacturer):
  - 500mg tablet:
  - 750mg tablet:
  - 25mg/mL oral solution:

**Moxifloxacin (MFX)**
- 400mg tablet:
Side Effects and Symptoms of Medication Toxicity

- **General** — GI upset, hepatotoxicity, hypersensitivity, dizziness, headaches, changes in heart rhythm, hypo- and hyper-glycemia, photosensitivity, arthralgias, insomnia, agitation, psychosis, paranoia, depression, peripheral neuropathy, thrush, seizures
- **Tendonitis** — Monitor for pain or rupture to tendons.
- **Cardiac** — Can cause prolongation of QTc

Recommended Assessments and Monitoring

- **Baseline, Monthly:**
  - Toxicity Assessment
    - Ask about tendon pain.
  - Laboratory
    - CBC, CMP
- **Other:**
  - **Do not take with** milk-based products, antacids, mineral supplements (iron or magnesium) within two hours of medication.
  - Avoid caffeinated foods and beverages.
  - Recommend sunscreen.
High Dose Isoniazid (INH)

(Adults 15mg/kg)

• 100mg tablet:

• 300mg tablet:

Side Effects and Symptoms of Medication Toxicity

• **General** — Anemia, agranulocytosis, vasculitis, decreased platelets, fever, chills, rash

• **Hepatotoxicity** — GI upset, nausea or vomiting (N/V), clay color stools, dark urine, yellow eyes, jaundice

• **Peripheral Neuropathy** — May cause numbness or tingling in extremities

• **Optic Neuropathy** — Pain, blurred vision, trouble seeing to the side, loss of color vision, flashing lights

Recommended Assessments and Monitoring

• **Baseline, monthly:**
  o Medication Assessments
    ▪ Toxicity Assessment
    ▪ Peripheral Neuropathy Monitoring
  o Laboratory
    ▪ Liver Function Tests (LFTs)

• **Other:**
  o **Add Vitamin B6** to regimen.
  o Take one hour before or two hours after antacids.
  o May interact with other drugs and foods. Avoid foods and drinks that contain tyramine. Monitor for [serotonin syndrome](#).
**Linezolid (LZD)**

- 600mg tablet:

- 100mg/5mL oral suspension:

---

**Side Effects and Symptoms of Medication Toxicity**

- **General** — Neuropathy, GI upset, change in vision, headaches, severe diarrhea, rash
- **Hematological** — Lactic acidosis, bone marrow suppression, anemia, thrombocytopenia, pancytopenia (confusion, SOB, rapid pulse, fever, chills, dizziness, unusual bleeding or bruising, petechiae, purpura, bruising, change in urinary frequency, black or tarry stools, unusual tiredness or weakness, signs and symptoms of infection, such as pale skin, lips, or nail beds)
- **Peripheral Neuropathy** — Numbness or tingling in extremities; may be permanent; usually occurs after 12–20 weeks of treatment
- **Optic Neuropathy** — Pain, blurred vision, trouble seeing to the side, loss of color vision, flashing lights; may be irreversible; usually occurs after 12—20 weeks of treatment
Recommended Assessments and Monitoring

- **Baseline, monthly:**
  - Medication Assessments
    - Toxicity Assessment
    - Peripheral Neuropathy Monitoring
    - Visual Acuity
    - Ishihara Plates
  - Laboratory
    - CBC, CMP

  *Some guidelines recommend weekly measurements of CBC during the initial phase. DSHS recommends consultation with a DSHS-recognized TB medical consultant.*

- **Other:**
  - Add **Vitamin B6** to regimen.
  - Monitor blood pressure.
  - May interact with other drugs and foods. Avoid foods and drinks that contain tyramine. Monitor for [serotonin syndrome](#).
Para-Aminosalicylic Acid (PAS)

- 4g packet:

Side Effects and Symptoms of Medication Toxicity

- **General** — GI upset, diarrhea, hepatotoxicity, rash, severe itching or hives, hypokalemia
- **Hypothyroidism** — Unusual bruising or bleeding, increased tiredness, hair loss, skin changes, trouble concentrating, irritable, depression, irregular menses, metallic taste, salivation, gynecomastia, impotence

Recommended Assessments and Monitoring

- **Baseline:**
  - Monthly Toxicity Assessment
  - Laboratory
    - CBC, CMP and TSH
- **Monthly:**
  - Toxicity Assessment
  - CBC and CMP
- **Every three months:**
  - TSH
- **Other:**
  - Sprinkle over applesauce or yogurt or mix with acidic juice.
  - Do not chew granules.
  - Refrigerate.
  - Avoid alcohol.
Pretomanid (Pa)

Used as part of the Bedaquiline, Pretomanid, Linezolid (BPaL) Regimen

- 200mg tablet:

Side Effects and Symptoms of Medication Toxicity

- **General** — Peripheral neuropathy, acne, anemia, nausea, vomiting, headache, indigestion, decreased appetite, rash, itching, abdominal pain, stabbing or burning pain in the chest when breathing, coughing or laughing, lower respiratory tract infection, liver problems, back pain, cough with or without blood, visual impairment, low blood sugar, abnormal loss of weight, diarrhea
- **Pretomanid** — The potential effect on male fertility is unknown. Counsel men of reproductive age.
- **Counsel patient** on BDQ and LZD side effects and toxicity symptoms.

Recommended Assessments and Monitoring

- **Baseline, monthly:**
  - Medication Assessments
    - Toxicity Assessment
  - Follow assessments and laboratory monitoring as per BDQ and LZD. If BPaL is prescribed with a FQN such as moxifloxacin, ensure FQN monitoring occurs.
- **Other:**
  - Take with food.
  - Swallow tablet whole.
  - Avoid alcohol or medications that affect the liver.
  - Counsel males of reproductive age regarding reproductive toxicities.
  - Avoid in nursing and pregnant women whose baby is known to be male.
Fact Sheets and Medication Resources

Fact sheets and supplemental resources support patient education. Some are patient-friendly while others are aimed at healthcare professionals for clinical understanding.

The following chart includes resources from the U.S. Centers for Disease Control and Prevention (CDC), the Food and Drug Administration (FDA), the Curry International TB Center, and Heartland National TB Center.

For additional resources, contact a local pharmacist or the Texas Department of State Health Services (DSHS) Pharmacy Branch.

<table>
<thead>
<tr>
<th>Medication</th>
<th>Source</th>
</tr>
</thead>
<tbody>
<tr>
<td>Amikacin</td>
<td>Heritage Pharmaceuticals — <a href="PDF">Prescribing Information — Amikacin</a></td>
</tr>
<tr>
<td></td>
<td>Curry International TB Center — <a href="PDF">Drug-Resistant Tuberculosis: A Survival Guide for Clinicians — Amikacin</a></td>
</tr>
<tr>
<td></td>
<td>Heartland National TB Center — <a href="PDF">Administration of Amikacin Injection</a></td>
</tr>
<tr>
<td>Bedaquiline</td>
<td>CDC — <a href="PDF">Treatment of Multidrug-Resistant Tuberculosis: Bedaquiline</a></td>
</tr>
<tr>
<td></td>
<td>Curry International TB Center — <a href="PDF">Drug-Resistant Tuberculosis: A Survival Guide for Clinicians — Bedaquiline</a></td>
</tr>
<tr>
<td></td>
<td>Janssen Package Insert — <a href="PDF">Medication Guide — Sirturo (Bedaquiline)</a></td>
</tr>
<tr>
<td>Clofazimine</td>
<td>FDA — <a href="PDF">Prescribing Information — Clofazimine</a></td>
</tr>
<tr>
<td></td>
<td>Curry International TB Center — <a href="PDF">Drug-Resistant Tuberculosis: A Survival Guide for Clinicians — Clofazimine</a></td>
</tr>
<tr>
<td>Drug</td>
<td>Source</td>
</tr>
<tr>
<td>----------------------</td>
<td>------------------------------------------------------------------------</td>
</tr>
<tr>
<td>Ethionamide</td>
<td>FDA — Prescribing Information — Ethionamide (PDF)</td>
</tr>
<tr>
<td>Isoniazid</td>
<td>FDA — Prescribing Information — Isoniazid (PDF)</td>
</tr>
<tr>
<td>Levofloxacin</td>
<td>FDA — Prescribing Information — Levofloxacin (PDF)</td>
</tr>
<tr>
<td>Linezolid</td>
<td>FDA — Prescribing Information – Linezolid (PDF)</td>
</tr>
<tr>
<td>Moxifloxacin</td>
<td>FDA — Prescribing Information – Avelox (PDF)</td>
</tr>
<tr>
<td>Para-amino Salicylic Acid</td>
<td>FDA — PASER Granules</td>
</tr>
<tr>
<td>Pretomanid</td>
<td>TB Alliance — <a href="https://example.com">Prescribing Information — Pretomanid</a> (PDF) and <a href="https://example.com">Pretomanid and the BPAL Regimen</a></td>
</tr>
<tr>
<td>------------</td>
<td>----------------------------------------------------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>Varies: second-line TB medication resources</td>
<td>Heartland National TB Center — <a href="https://example.com">Characteristics of Second-line Drugs for MDR-TB</a> (PDF); <a href="https://example.com">Tuberculosis Adverse Drug Events</a> (PDF); <a href="https://example.com">Tuberculosis Medication Drug and Food Interactions</a> (PDF)</td>
</tr>
</tbody>
</table>
Nursing Cheat Sheets

Cheat sheets are stand-alone references. Nurses may cut and save the cheat sheets to place on the back of a badge or in a folder for quick reference.

Quick Reference Laboratory Cheat Sheet, excluding CBC and CMP

<table>
<thead>
<tr>
<th>Lab</th>
<th>Medication</th>
</tr>
</thead>
<tbody>
<tr>
<td>Magnesium</td>
<td>AK, BDQ</td>
</tr>
<tr>
<td>Pregnancy Test</td>
<td>AK, CFZ</td>
</tr>
<tr>
<td>TSH</td>
<td>BDQ, ETA, PAS</td>
</tr>
</tbody>
</table>

Quick Reference Toxicity Assessment Cheat Sheet for Individual Medications

<table>
<thead>
<tr>
<th>Medication</th>
<th>Recommended Toxicity Monitoring</th>
</tr>
</thead>
<tbody>
<tr>
<td>Amikacin (AK)</td>
<td>Audiometry Testing</td>
</tr>
<tr>
<td></td>
<td>Vestibular Testing</td>
</tr>
<tr>
<td>Bedaquiline (BDQ)</td>
<td>ECG</td>
</tr>
<tr>
<td>Clofazimine (CFZ)</td>
<td>Mental Health Assessment</td>
</tr>
<tr>
<td>Cycloserine (CS)</td>
<td>Mental Health Assessment</td>
</tr>
<tr>
<td>Fluoroquinolones: Moxifloxacin (MFX) and Levofloxacin (LFX)</td>
<td>Monitor Tendon Pain</td>
</tr>
<tr>
<td>High Dose Isoniazid (INH)</td>
<td>Peripheral Neuropathy Monitoring</td>
</tr>
<tr>
<td>Linezolid (LZD)</td>
<td>Peripheral Neuropathy Monitoring</td>
</tr>
<tr>
<td></td>
<td>Visual Acuity</td>
</tr>
<tr>
<td></td>
<td>Ishihara Plates</td>
</tr>
<tr>
<td>Pretomanid, used with Bedaquiline and Linezolid (BPaL)</td>
<td>ECG</td>
</tr>
<tr>
<td></td>
<td>Peripheral Neuropathy Monitoring</td>
</tr>
<tr>
<td></td>
<td>Visual Acuity</td>
</tr>
<tr>
<td></td>
<td>Ishihara Plates</td>
</tr>
</tbody>
</table>
References


